FEMASYS INC. - COMMON STOCK

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

15 ноя 2023 06:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update

14 ноя 2023 06:00:00 Источник Nasdaq GlobeNewswire

Femasys Inc. EU MDR Final Audit Successfully Completed

26 окт 2023 07:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons

25 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Regains Compliance with Nasdaq Listing Requirements

11 окт 2023 06:00:00 Источник Nasdaq GlobeNewswire

Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine

04 окт 2023 07:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. MDSAP Surveillance Audit Successfully Completed

03 окт 2023 07:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate

27 сен 2023 07:00:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution

25 сен 2023 16:25:04 Источник Nasdaq GlobeNewswire

Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control

20 сен 2023 07:30:09 Источник Nasdaq GlobeNewswire

Femasys to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

06 сен 2023 07:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Obtains Medical Device Establishment License from Health Canada

31 авг 2023 07:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update

10 авг 2023 07:00:01 Источник Nasdaq GlobeNewswire

Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc

03 авг 2023 07:45:00 Источник Nasdaq GlobeNewswire

Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemBloc for Female Permanent Birth Control

27 июл 2023 07:45:00 Источник Nasdaq GlobeNewswire

Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women

26 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences

15 июн 2023 07:00:00 Источник Nasdaq GlobeNewswire

Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023

14 июн 2023 07:00:01 Источник Nasdaq GlobeNewswire

Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada

08 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023

11 май 2023 15:05:01 Источник Nasdaq GlobeNewswire